피플바이오
Financials
Valuation Metrics
피플바이오's Market Cap is ₩136B. At end of 2025 it was ₩260B. Ranked #2400 of 2,436 in KR market (top 99%), #1618 of 1,649 on KOSDAQ (top 98%), #233 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 100%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 13.64B KRW | KR#2,400/2,436 Sec#233/234 |
| Revenue | 2.71B KRW | KR#2,380/2,436 Sec#211/234 |
| Net Income | -16.94B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 47.45B KRW | KR#2,206/2,436 Sec#201/234 |
| Net Assets | 29.77B KRW | KR#2,168/2,436 Sec#192/234 |
| Employees | 60 | KR#1,944/2,436 Sec#170/234 |
| Value | ||
| P/B | 0.46x | KR#711/2,436 Sec#24/234 |
| P/S | 5.03x | KR#2,144/2,436 Sec#141/234 |
| Profitability | ||
| ROE | -56.91% | KR#2,288/2,436 Sec#204/234 |
| ROA | -35.70% | KR#2,330/2,436 Sec#212/234 |
| Op. Margin | -267.76% | KR#2,352/2,436 Sec#193/234 |
| Revenue Growth | -17.48% | KR#2,025/2,436 Sec#184/234 |
| Financial Health | ||
| Debt Ratio | 159.40% | KR#1,308/2,436 Sec#149/234 |
| Total Debt | 12.84B KRW | KR#1,532/2,436 Sec#136/234 |
| Cash | 2.99B KRW | KR#2,157/2,436 Sec#203/234 |
| Current Ratio | 0.46x | KR#2,275/2,436 Sec#222/234 |
| Performance | ||
| 1Y Return | -77.33% | KR#2,392/2,436 Sec#232/234 |
| 1M Return | -28.17% | KR#2,342/2,436 Sec#229/234 |
| From 52W High | -80.45% | KR#2,359/2,436 Sec#223/234 |
| 1Y MDD | -78.79% | KR#2,266/2,436 Sec#206/234 |
| Trading | ||
| Foreign Own. | 0.95% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -679 KRW | KR—/2,436 Sec—/234 |
| BPS | 1,240 KRW | KR#2,231/2,436 Sec#200/234 |
Company Info
PeopleBio, established in 2002, develops and manufactures blood diagnostic products for conformational protein diseases, and was listed on KOSDAQ in 2020. It specializes in early diagnosis blood test products for Alzheimer's disease, offering simple ELISA-based tests at around 100,000 won, based on SI-MDS technology for measuring oligomeric proteins. The company is expanding its technology through natural product-based Alzheimer's disease treatment development via its subsidiary Pharmacobio and Parkinson's disease diagnosis digital biomarker development with J.US. PeopleBio is headquartered in Seongnam-si, Gyeonggi-do.